News & Updates

New drug applications approved by US FDA as of 16-31 July 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Frailty appears to be a familiar feature among patients with multiple forms of vasculitis, suggesting a substantial subset of patients at risk for worse outcomes, suggests a study.

Being underweight puts adolescents at risk of osteoporosis in adulthood, and this risk further increases in those who remain underweight in their adult life, according to a retrospective study.

Patients with systemic lupus erythematosus (SLE) with low levels of vitamin D tend to have a more severe form of the disease, according to a systematic review and meta-analysis.

The standard intensity for anticoagulation is enough to protect adult southeast Asians with moderate-to-severe rheumatic mitral stenosis (MS) against thromboembolism, with an acceptable risk of major bleeding, according to a study.

Walking a longer distance or for a longer time can reduce the risk of developing chronic low back pain.

Treatment with bimekizumab showed sustained efficacy for up to 3 years in patients with nonradiographic (nr) and radiographic (r) axial spondyloarthritis (axSpA), based on a pooled analysis of the two phase III studies (BE MOBILE 1 and 2) and combined open-label extension (OLE) study presented at EULAR 2025.

In patients with rheumatoid arthritis (RA), high disease-associated central nervous system (CNS) pain activation on functional MRI (fMRI) brain scan may help predict clinical response to TNF inhibitor treatment, as shown in a phase III study.

Treatment with inebilizumab reduced the risk of disease flares in patients with immunoglobulin G4-related disease (IgG4-RD) irrespective of sex, age, or race, according to a subgroup analysis of the phase III MITIGATE study presented at EULAR 2025.